Novel Virus-Like Particle (VLP)-Based Vaccines Against Alzheimer's Disease Tau Pathology
Highly efficient, safe, economical, andstate-of-the-art immunotherapy approach based on a Virus-Like Particle (VLP)platformTargets four disease-related modifications inmicrotubule associated tau protein (MAPT)This VLP-based immunotherapy, targeting p-MAPT,provides a potential opportunity for developing future therapies against p-MAPT/NFT-inducedneurodegenerative alterationsElicits antibodies against pathological tauwithout inducing a severe inflammatory responseVaccination leads to significant improvements inrecognition and spatial memoryVaccination decreases neurofibrillary tangles inthe hippocampus and cortex in a mouse model of tauopathyPrevents neuronal cell loss induced by taupathologyApplicable to neurodegenerative tauopathies (suchas Alzheimer’s Disease) and tauopathy-resultant from TBI and CTE
Aunique virus-like particle (VPL)-based platform technology to develop vaccinesagainst tauopathies.
美國
